Sihuan Pharmaceutical Forecasts Strong 2025 Profit on Booming Aesthetics and Drug Growth

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has provided an announcement.

Sihuan Pharmaceutical issued a positive profit alert, guiding 2025 revenue of at least RMB2.5 billion, up about 30% year on year, and net profit of no less than RMB150 million. The group’s medical aesthetics segment became its largest revenue and profit contributor, generating over RMB1.4 billion in revenue and more than RMB700 million in segment profit, both rising over 90% and supported by strong uptake of core products such as botulinum toxin Letybo.

The innovative drug business is shifting from an investment to a harvest phase, as subsidiaries Xuanzhu Biopharm and Huisheng Biopharm delivered strong revenue growth, more approved products, and better R&D cost efficiency, improving the profit mix. A solid balance sheet, multiple share repurchases, and the spin-off listing of Xuanzhu Biopharm enhanced equity value and funding flexibility, while new aesthetic approvals, an expanded full-matrix product lineup, and a distribution deal with Swiss firm Suisselle to enter EU markets position Sihuan as a comprehensive aesthetic solutions provider with stronger long-term growth prospects.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group is a Hong Kong–listed pharmaceutical group with growing focuses on medical aesthetics and innovative drugs. Its portfolio now spans botulinum toxin, poly-L-lactic acid products, collagen stimulators, skin boosters, hyaluronic acid fillers, photoelectric devices, and a range of novel pharmaceutical products, targeting both the China market and overseas expansion through international partnerships.

Average Trading Volume: 26,666,800

Technical Sentiment Signal: Buy

Current Market Cap: HK$15.3B

See more insights into 0460 stock on TipRanks’ Stock Analysis page.